IFM 2026 opens in Dubai with 900+ delegates as clinics face prevention and AI choices

The 13th International Family Medicine Conference & Exhibition (IFM 2026) opened at Dubai World Trade Centre on 25 August 2026, putting prevention, AI screening and pharmacy-linked primary care in front of more than 900 healthcare professionals from 10 countries.

The highest-stakes readers are clinic COOs, medical directors and payer network teams. IFM is a conference, not a new rule. Its agenda still signals where Dubai Health Authority (DHA)-licensed clinics may face procurement, clinical governance and patient demand decisions over the next 12 months. Department of Health Abu Dhabi (DOH Abu Dhabi) providers and Ministry of Health and Prevention (MOHAP)-licensed facilities in the northern emirates should read the same agenda through their own licensing and insurance contracts.

What opened in Dubai

According to Big News Network, citing WAM, the three-day event includes more than 45 speakers, over 18 scientific sessions, more than 70 scientific posters and eligibility for 21 CME credits. The official IFM 2026 event site lists the dates as 25-27 August 2026 at Dubai World Trade Centre.

"Family medicine is more than the starting point of a patient's journey through the healthcare system; it is the foundation of community health and sustainable healthcare systems." Amb. Prof. Abdulsalam AlMadani, Chairman of IFM

The programme covers wearable devices, AI-enabled arrhythmia screening, travel medicine, cardiometabolic disease, cancer detection using TKTL1 enzyme expression, gut health, women's health, diabetes, obesity, addiction, functional medicine and autism and ADHD. Exhibitors named in the WAM report include American Hospital Dubai, Seers Tech and Omron.

Why clinics and insurers should care

For Dubai clinic operators, the commercial question is whether family medicine becomes the channel for earlier diagnosis rather than episodic GP visits. A primary-care clinic evaluating AI electrocardiography, remote monitoring or wearable integrations should first check whether the service falls inside its licensed activity on DHA Sheryan. In Dubai, DHA Sheryan is also the route for new facility licensing, and DHA lists 5 working days as the average processing time for a new healthcare facility licence application before activation and inspection steps.

For insurers, the question is benefit design. AI arrhythmia checks, cancer risk tests and obesity programmes can move costs earlier in the patient journey. Whether that lowers claims depends on coding, referral rules and utilisation controls. Providers should ask payers for written coverage positions before marketing new screening packages. For Daman, Thiqa and Sukoon networks, the actionable number is the contract tariff or pre-authorisation rule in the payer portal, not the conference brochure.

• COOs: map each new screening workflow to DHA, DOH Abu Dhabi or MOHAP facility scope before purchase.
• CFOs: compare payer tariff coverage with device lease costs, staff time and consumables.
• Medical directors: require local clinical protocols for false positives, referrals and documentation.
• Pharmacy heads: verify whether medication counselling, chronic refills and screening referrals are allowed under the pharmacy licence category.

Patients are likely to see more bundled prevention offers after IFM. Operators should avoid quoting a UAE-wide price for AI screening, longevity testing or functional medicine packages. There is no single public tariff for these services. The practical route is to check the clinic's approved price list, payer network schedule and whether the patient is cash-pay, employer-insured or government-funded.

The pharmacy angle

The pharmacy relevance is direct because family medicine demand is tied to chronic prescriptions, refill adherence, cardiometabolic risk and pharmacist counselling. In Abu Dhabi, DOH says its health system includes more than 950 pharmacies, more than 770 clinics and more than 1,520 medical centres, according to its public website. That creates a large referral and dispensing market around diabetes, obesity, hypertension and women's health services discussed at IFM.

Dubai pharmacies should check DHA's Dubai Medical Registry before expanding screening partnerships. Abu Dhabi pharmacies should use DOH Abu Dhabi's pharmacy finder and facility tools. Northern emirates pharmacies should use the MOHAP medical facilities directory for licensed facility checks. The same discipline applies to branded wellness campaigns: claims, referrals and medical advertising approvals vary by emirate and licence type.

The next test is whether IFM's clinical themes convert into contracts. Clinic groups should watch payer circulars, DHA and DOH Abu Dhabi guidance on digital health, and MOHAP licensing updates for the northern emirates through Q4 2026. For pharmacy network planning, use the UAE Open Healthcare Directory to identify licensed pharmacy providers before approaching partners or building referral lists.